1
|
Katrak S, Wang R, Barry P. Costs of treating multidrug-resistant TB in California in 2022. Int J Tuberc Lung Dis 2023; 27:864-866. [PMID: 37880888 PMCID: PMC10599414 DOI: 10.5588/ijtld.23.0150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2023] [Accepted: 06/28/2023] [Indexed: 10/27/2023] Open
Affiliation(s)
- S Katrak
- Tuberculosis Control Branch, California Department of Public Health, Richmond, CA, Division of Infectious Diseases, University of California, San Francisco, CA, USA
| | - R Wang
- Tuberculosis Control Branch, California Department of Public Health, Richmond, CA
| | - P Barry
- Tuberculosis Control Branch, California Department of Public Health, Richmond, CA, Division of Infectious Diseases, University of California, San Francisco, CA, USA
| |
Collapse
|
2
|
Austin EJ, Chen J, Briggs ES, Ferro L, Barry P, Heald A, Merrill JO, Curran GM, Saxon AJ, Fortney JC, Ratzliff AD, Williams EC. Integrating Opioid Use Disorder Treatment Into Primary Care Settings. JAMA Netw Open 2023; 6:e2328627. [PMID: 37566414 PMCID: PMC10422185 DOI: 10.1001/jamanetworkopen.2023.28627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Accepted: 06/29/2023] [Indexed: 08/12/2023] Open
Abstract
Importance Medication for opioid use disorder (MOUD) (eg, buprenorphine and naltrexone) can be offered in primary care, but barriers to implementation exist. Objective To evaluate an implementation intervention over 2 years to explore experiences and perspectives of multidisciplinary primary care (PC) teams initiating or expanding MOUD. Design, Setting, and Participants This survey-based and ethnographic qualitative study was conducted at 12 geographically and structurally diverse primary care clinics that enrolled in a hybrid effectiveness-implementation study from July 2020 to July 2022 and included PC teams (prescribing clinicians, nonprescribing behavioral health care managers, and consulting psychiatrists). Survey data analysis was conducted from February to April 2022. Exposure Implementation intervention (external practice facilitation) to integrate OUD treatment alongside existing collaborative care for mental health services. Measures Data included (1) quantitative surveys of primary care teams that were analyzed descriptively and triangulated with qualitative results and (2) qualitative field notes from ethnographic observation of clinic implementation meetings analyzed using rapid assessment methods. Results Sixty-two primary care team members completed the survey (41 female individuals [66%]; 1 [2%] American Indian or Alaskan Native, 4 [7%] Asian, 5 [8%] Black or African American, 5 [8%] Hispanic or Latino, 1 [2%] Native Hawaiian or Other Pacific Islander, and 46 [4%] White individuals), of whom 37 (60%) were between age 25 and 44 years. An analysis of implementation meetings (n = 362) and survey data identified 4 themes describing multilevel factors associated with PC team provision of MOUD during implementation, with variation in their experience across clinics. Themes characterized challenges with clinical administrative logistics that limited the capacity to provide rapid access to care and patient engagement as well as clinician confidence to discuss aspects of MOUD care with patients. These challenges were associated with conflicting attitudes among PC teams toward expanding MOUD care. Conclusions and Relevance The results of this survey and qualitative study of PC team perspectives suggest that PC teams need flexibility in appointment scheduling and the capacity to effectively engage patients with OUD as well as ongoing training to maintain clinician confidence in the face of evolving opioid-related clinical issues. Future work should address structural challenges associated with workload burden and limited schedule flexibility that hinder MOUD expansion in PC settings.
Collapse
Affiliation(s)
- Elizabeth J. Austin
- Department of Health Systems and Population Health, School of Public Health University of Washington, Seattle
| | - Jessica Chen
- Department of Health Systems and Population Health, School of Public Health University of Washington, Seattle
| | - Elsa S. Briggs
- Department of Health Systems and Population Health, School of Public Health University of Washington, Seattle
| | - Lori Ferro
- Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle
| | - Paul Barry
- Advancing Integrated Mental Health Solutions Center, University of Washington, Seattle
| | - Ashley Heald
- Advancing Integrated Mental Health Solutions Center, University of Washington, Seattle
| | - Joseph O. Merrill
- Department of Medicine, School of Medicine, University of Washington, Seattle
| | - Geoffrey M. Curran
- Departments of Pharmacy Practice and Psychiatry, University of Arkansas for Medical Sciences, Little Rock
- Central Arkansas Veterans Health Care System
| | - Andrew J. Saxon
- Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle
- Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound, Seattle, Washington
| | - John C. Fortney
- Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle
- Advancing Integrated Mental Health Solutions Center, University of Washington, Seattle
- Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound, Seattle, Washington
| | - Anna D. Ratzliff
- Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle
- Advancing Integrated Mental Health Solutions Center, University of Washington, Seattle
| | - Emily C. Williams
- Department of Health Systems and Population Health, School of Public Health University of Washington, Seattle
- Center of Innovation for Veteran-Centered and Value-Driven Care, Health Services Research and Development, VA Puget Sound, Seattle, Washington
| |
Collapse
|
3
|
Austin EJ, Briggs ES, Ferro L, Barry P, Heald A, Curran GM, Saxon AJ, Fortney J, Ratzliff AD, Williams EC. Integrating Routine Screening for Opioid Use Disorder into Primary Care Settings: Experiences from a National Cohort of Clinics. J Gen Intern Med 2023; 38:332-340. [PMID: 35614169 PMCID: PMC9132563 DOI: 10.1007/s11606-022-07675-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Accepted: 05/11/2022] [Indexed: 12/01/2022]
Abstract
BACKGROUND The U.S. Preventive Services Task Force recommends routine population-based screening for drug use, yet screening for opioid use disorder (OUD) in primary care occurs rarely, and little is known about barriers primary care teams face. OBJECTIVE As part of a multisite randomized trial to provide OUD and behavioral health treatment using the Collaborative Care Model, we supported 10 primary care clinics in implementing routine OUD screening and conducted formative evaluation to characterize early implementation experiences. DESIGN Qualitative formative evaluation. APPROACH Formative evaluation included taking detailed observation notes at implementation meetings with individual clinics and debriefings with external facilitators. Observation notes were analyzed weekly using a Rapid Assessment Process guided by the Consolidated Framework for Implementation Research, with iterative feedback from the study team. After clinics launched OUD screening, we conducted structured fidelity assessments via group interviews with each site to evaluate clinic experiences with routine OUD screening. Data from observation and structured fidelity assessments were combined into a matrix to compare across clinics and identify cross-cutting barriers and promising implementation strategies. KEY RESULTS While all clinics had the goal of implementing population-based OUD screening, barriers were experienced across intervention, individual, and clinic setting domains, with compounding effects for telehealth visits. Seven themes emerged characterizing barriers, including (1) challenges identifying who to screen, (2) complexity of the screening tool, (3) staff discomfort and/or hesitancies, (4) workflow barriers that decreased screening follow-up, (5) staffing shortages and turnover, (6) discouragement from low screening yield, and (7) stigma. Promising implementation strategies included utilizing a more universal screening approach, health information technology (HIT), audit and feedback, and repeated staff trainings. CONCLUSIONS Integrating population-based OUD screening in primary care is challenging but may be made feasible via implementation strategies and tailored practice facilitation that standardize workflows via HIT, decrease stigma, and increase staff confidence regarding OUD.
Collapse
Affiliation(s)
- Elizabeth J Austin
- Department of Health Systems and Population Health, School of Public Health, University of Washington, Box 351621, Seattle, WA, 98105, USA.
| | - Elsa S Briggs
- Department of Health Systems and Population Health, School of Public Health, University of Washington, Box 351621, Seattle, WA, 98105, USA
| | - Lori Ferro
- Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle, WA, USA
| | - Paul Barry
- Advancing Integrated Mental Health Solutions (AIMS) Center, University of Washington, Seattle, WA, USA
| | - Ashley Heald
- Advancing Integrated Mental Health Solutions (AIMS) Center, University of Washington, Seattle, WA, USA
| | - Geoffrey M Curran
- Departments of Pharmacy Practice and Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Central Arkansas Veterans Health Care System, Little Rock, AR, USA
| | - Andrew J Saxon
- Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle, WA, USA
- Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound, Seattle, WA, USA
| | - John Fortney
- Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle, WA, USA
- Advancing Integrated Mental Health Solutions (AIMS) Center, University of Washington, Seattle, WA, USA
- Center of Innovation for Veteran-Centered and Value-Driven Care, Health Services Research & Development, VA Puget Sound, Seattle, WA, USA
| | - Anna D Ratzliff
- Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle, WA, USA
- Advancing Integrated Mental Health Solutions (AIMS) Center, University of Washington, Seattle, WA, USA
| | - Emily C Williams
- Department of Health Systems and Population Health, School of Public Health, University of Washington, Box 351621, Seattle, WA, 98105, USA
- Center of Innovation for Veteran-Centered and Value-Driven Care, Health Services Research & Development, VA Puget Sound, Seattle, WA, USA
| |
Collapse
|
4
|
Mensch R, Dahab T, Barry P, Murphy J. 169 THE SPECTRUM, ASSESSMENT AND DIAGNOSIS OF NEUROVASCULAR OPHTHALMIC PRESENTATIONS REFERRED TO AN ACUTE MEDICAL UNIT. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Ocular emergencies may require urgent intervention to prevent vision loss. Physicians must be confident in recognizing their presentations. However, literature published in this area is lacking.
Methods
This study assesses the consistency of the assessment of patients with neurovascular ophthalmic conditions in the Acute Medical Unit (AMU) at an Irish tertiary healthcare centre . Conditions of interest include retinal artery and vein occlusions, ischaemic optic neuropathies, and cranial nerve palsies (III, IV, and VI). Research questions to be addressed: 1. The percentage of patients referred from Eye Casualty Services (ECS) to the AMU with neurovascular ophthalmic presentations 2. The investigations performed to diagnose neurovascular ophthalmic conditions 3. How the diagnostic approach used in the AMU compares to that recommended by the literature 4. The accuracy of ECS referral diagnoses. This is an audit of 164 patients attending the AMU during a one-year period who were diagnosed with ophthalmological conditions.
Results
Of patients studied, 58 (35%) were diagnosed with conditions of interest. The most common neurovascular ophthalmic diagnosis was cranial nerve palsy (21, 36%). Among neurovascular patients, routine laboratory investigations were performed in over 90% of cases. Routine imaging was performed in over 80% of cases. Referral diagnoses from the ECS accompanied 13 (22%) of neurovascular patients, all of which were accurate.
Conclusion
Neurovascular ophthalmic conditions represent a significant proportion of ECS referrals to the AMU, and most aren’t diagnosed until after leaving the ECS. Laboratory and imaging investigations may be inappropriately utilized in some cases. More research is needed in this area.
Collapse
Affiliation(s)
- R Mensch
- University College Cork , Cork, Ireland
- Cork University Hospital Department of Medicine, , Cork, Ireland
| | - T Dahab
- Cork University Hospital Department of Medicine, , Cork, Ireland
| | - P Barry
- Cork University Hospital Department of Medicine, , Cork, Ireland
| | - J Murphy
- Cork University Hospital Department of Medicine, , Cork, Ireland
| |
Collapse
|
5
|
Murphy J, Kelly R, Cathasaigh CN, Murphy D, Cloney T, Hayes K, Arrigan G, O'Sullivan A, Barry P, James K, Healy L. 168 AN EXPLORATION OF ATRIAL FIBRILLATION AND ANTICOAGULATION IN STROKE PATIENTS WHO UNDERGO THROMBECTOMY IN A TERTIARY THROMBECTOMY CENTRE. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Atrial Fibrillation is a significant cause of ischaemic stroke. Prevalence of atrial fibrillation in patients requiring thrombectomy is approximately 33%. Embolic thrombi which develop due to Atrial fibrillation may become targets for clot removal by thrombectomy in appropriate patients. Anticoagulation is one of the mainstays of treatment for atrial fibrillation.
Methods
A list of patients who had thrombectomy performed for ischaemic stroke in 2021 was compiled. Charts were reviewed to establish the prevalence of atrial fibrillation and the rates of appropriate dosing of anticoagulant. Of those who were not anticoagulated, we aimed to establish if there was a clear reason for this. This was performed in a tertiary referral centre with 24/7 access to thrombectomy.
Results
97 patients had thrombectomy performed for ischaemic stroke in 2021. 34/97(35%) had atrial fibrillation (21/97 pre-existing , 13/97 newly diagnosed on admission). 15/21 were anticoagulated and 6/21 were not anticoagulated at the time of their stroke. 5/6 had a clear reason documented for stopping anticoagulation. One patient had stopped anticoagulation due to cost. Of those with atrial fibrillation who were anticoagulated at the time of their stroke, 11 were anticoagulated with a Direct-Acting AntiCoagulant (DOAC) and four were anticoagulated with Warfarin. Of the Warfarin group, just one patients’ INR was therapeutic at the time of their stroke. Of the DOAC group, all were on the appropriate dose.
Conclusion
Stroke patients requiring thrombectomy are a group who may suffer the largest strokes. Incidence of atrial fibrillation was similar to previous studies. It was encouraging that there was a documented reason for all patients who were not anticoagulated, and that the DOAC dose was appropriate. Issues with therapeutic levels of Warfarin are further highlighted here. This study concludes that we may not be as bad at anticoagulation as we may think.
Collapse
Affiliation(s)
- J Murphy
- Cork University Hospital Department of Geriatrics and Stroke Medicine, , Cork, Ireland
| | - R Kelly
- Cork University Hospital Department of Geriatrics and Stroke Medicine, , Cork, Ireland
| | - CN Cathasaigh
- Cork University Hospital Department of Geriatrics and Stroke Medicine, , Cork, Ireland
| | - D Murphy
- Cork University Hospital Department of Geriatrics and Stroke Medicine, , Cork, Ireland
| | - T Cloney
- Cork University Hospital Department of Geriatrics and Stroke Medicine, , Cork, Ireland
| | - K Hayes
- Cork University Hospital Department of Geriatrics and Stroke Medicine, , Cork, Ireland
| | - G Arrigan
- Cork University Hospital Department of Geriatrics and Stroke Medicine, , Cork, Ireland
| | - A O'Sullivan
- Cork University Hospital Department of Geriatrics and Stroke Medicine, , Cork, Ireland
| | - P Barry
- Cork University Hospital Department of Geriatrics and Stroke Medicine, , Cork, Ireland
| | - K James
- Cork University Hospital Department of Geriatrics and Stroke Medicine, , Cork, Ireland
| | - L Healy
- Cork University Hospital Department of Geriatrics and Stroke Medicine, , Cork, Ireland
| |
Collapse
|
6
|
Sapru K, Patterson S, Barry P, Bright-Thomas R, Jones A. 20 Impact of elexacaftor/tezacaftor/ivacaftor therapy on older adults with cystic fibrosis. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00711-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
7
|
Tewkesbury D, Jones A, Athwal V, Bright-Thomas R, Barry P. WS02.04 Liver function test abnormalities in cystic fibrosis patients commenced on ELX/TEZ/IVA in a large adult cystic fibrosis centre over 12 months. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00162-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Catanuto G, Rocco N, Maglia A, Barry P, Karakatsanis A, Heil J, Karakatsanis A, Weber WP, Gonzalez E, Chatterjee A, Urban C, Sund M, Paulinelli RR, Markopoulos C, Rubio IT, Masannat YA, Meani F, Koppiker CB, Holcombe C, Benson JR, Dietz JR, Walker M, Mátrai Z, Shaukat A, Gulluoglu B, Brenelli F, Fitzal F, Mele M, Sgroi G, Russo G, Pappalardo F, Nava M. Text mining and word embedding for classification of decision making variables in breast cancer surgery. European Journal of Surgical Oncology 2022; 48:1503-1509. [DOI: 10.1016/j.ejso.2022.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 03/04/2022] [Indexed: 10/18/2022]
|
9
|
Abstract
BACKGROUND: Hospitalization is a costly event that affects more than half of all TB patients in the United States. State-level hospitalization data are crucial in estimating the cost of TB disease and the financial impact of preventing TB.METHODS: We used California administrative hospital discharge data from 2009 to 2017 to characterize TB hospitalizations in comparison with non-neonatal, non-maternal hospitalizations. TB hospitalization was defined as a hospitalization with a TB ICD-9/10 code as the primary diagnosis. We estimated hospitalization costs in 2017 dollars from reported charges using cost-to-charge ratios.RESULTS: In comparison to persons hospitalized for other conditions, persons hospitalized for TB in 2017 were more likely to be male, of working age, and Asian/Pacific Islander. The median cost for TB hospitalizations was US$22,807 vs. US$11,568 for other hospitalizations. The median length of stay for TB hospitalizations was 12 days compared to 3 days for other hospitalizations. Medicaid was expected to pay for 50% of TB hospitalizations costing US$21,438,208.CONCLUSIONS: Societal cost estimates of TB hospitalization should be updated to reflect long hospital stays and the disproportionate burden on working age persons. This analysis enhances our understanding of the high cost of TB care and underscores the costs averted if TB cases are prevented.
Collapse
Affiliation(s)
- A Readhead
- TB Control Branch, California Department of Public Health, Richmond, CA
| | - G Cooksey
- Infectious Disease Branch, California Department of Public Health, Sacramento, CA, USA
| | - J Flood
- TB Control Branch, California Department of Public Health, Richmond, CA
| | - P Barry
- TB Control Branch, California Department of Public Health, Richmond, CA
| |
Collapse
|
10
|
Tewkesbury D, Looi E, Green H, Barry P, Edwards G, Smith M, Cullen M, Jones. A. WS13.6 Clinical outcomes in patients with cystic fibrosis with Exophiala dermatitidis grown in sputum. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)00992-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Puckey M, Phillips B, Oxley H, Oldaker R, Barry P, Trust C, Donnelly M. P204 The what-if's….considering the psychological impacts of CFTR modulators. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01229-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Lecordier L, Uzureau S, Vanwalleghem G, Deleu M, Crowet JM, Barry P, Moran B, Voorheis P, Dumitru AC, Yamaryo-Botté Y, Dieu M, Tebabi P, Vanhollebeke B, Lins L, Botté CY, Alsteens D, Dufrêne Y, Pérez-Morga D, Nolan DP, Pays E. The Trypanosoma Brucei KIFC1 Kinesin Ensures the Fast Antibody Clearance Required for Parasite Infectivity. iScience 2020; 23:101476. [PMID: 32889430 PMCID: PMC7479354 DOI: 10.1016/j.isci.2020.101476] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Revised: 07/30/2020] [Accepted: 08/17/2020] [Indexed: 12/24/2022] Open
Abstract
Human innate immunity to Trypanosoma brucei involves the trypanosome C-terminal kinesin TbKIFC1, which transports internalized trypanolytic factor apolipoprotein L1 (APOL1) within the parasite. We show that TbKIFC1 preferentially associates with cholesterol-containing membranes and is indispensable for mammalian infectivity. Knockdown of TbKIFC1 did not affect trypanosome growth in vitro but rendered the parasites unable to infect mice unless antibody synthesis was compromised. Surface clearance of Variant Surface Glycoprotein (VSG)-antibody complexes was far slower in these cells, which were more susceptible to capture by macrophages. This phenotype was not due to defects in VSG expression or trafficking but to decreased VSG mobility in a less fluid, stiffer surface membrane. This change can be attributed to increased cholesterol level in the surface membrane in TbKIFC1 knockdown cells. Clearance of surface-bound antibodies by T. brucei is therefore essential for infectivity and depends on high membrane fluidity maintained by the cholesterol-trafficking activity of TbKIFC1.
Collapse
Affiliation(s)
- Laurence Lecordier
- Laboratory of Molecular Parasitology, IBMM, Université Libre de Bruxelles, 12, rue des professeurs Jeener et Brachet, 6041 Gosselies, Belgium
| | - Sophie Uzureau
- Laboratory of Molecular Parasitology, IBMM, Université Libre de Bruxelles, 12, rue des professeurs Jeener et Brachet, 6041 Gosselies, Belgium
| | - Gilles Vanwalleghem
- Laboratory of Molecular Parasitology, IBMM, Université Libre de Bruxelles, 12, rue des professeurs Jeener et Brachet, 6041 Gosselies, Belgium
| | - Magali Deleu
- Laboratory of Molecular Biophysics at Interface (LBMI), University of Liège-Gembloux Agro Bio Tech, 2, Passage des Déportés, 5030 Gembloux, Belgium
| | - Jean-Marc Crowet
- Laboratory of Molecular Biophysics at Interface (LBMI), University of Liège-Gembloux Agro Bio Tech, 2, Passage des Déportés, 5030 Gembloux, Belgium
| | - Paul Barry
- School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland
| | - Barry Moran
- School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland
| | - Paul Voorheis
- School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland
| | - Andra-Cristina Dumitru
- Louvain Institute of Biomolecular Science and Technology, Catholic University of Louvain, Croix du Sud 4-5, 1348 Louvain-la-Neuve, Belgium
| | - Yoshiki Yamaryo-Botté
- Institute for Advanced Biosciences, CNRS UMR5309, Université Grenoble Alpes, INSERM U1209, 38700 La Tronche, France
| | - Marc Dieu
- MaSUN, Mass Spectrometry Facility, University of Namur, 61 Rue de Bruxelles, 5000 Namur, Belgium
| | - Patricia Tebabi
- Laboratory of Molecular Parasitology, IBMM, Université Libre de Bruxelles, 12, rue des professeurs Jeener et Brachet, 6041 Gosselies, Belgium
| | - Benoit Vanhollebeke
- Laboratory of Neurovascular Signaling, Université Libre de Bruxelles, 12, Rue des Profs Jeener et Brachet, 6041 Gosselies, Belgium
| | - Laurence Lins
- Laboratory of Molecular Biophysics at Interface (LBMI), University of Liège-Gembloux Agro Bio Tech, 2, Passage des Déportés, 5030 Gembloux, Belgium
| | - Cyrille Y. Botté
- Institute for Advanced Biosciences, CNRS UMR5309, Université Grenoble Alpes, INSERM U1209, 38700 La Tronche, France
| | - David Alsteens
- Louvain Institute of Biomolecular Science and Technology, Catholic University of Louvain, Croix du Sud 4-5, 1348 Louvain-la-Neuve, Belgium
| | - Yves Dufrêne
- Louvain Institute of Biomolecular Science and Technology, Catholic University of Louvain, Croix du Sud 4-5, 1348 Louvain-la-Neuve, Belgium
| | - David Pérez-Morga
- Laboratory of Molecular Parasitology, IBMM, Université Libre de Bruxelles, 12, rue des professeurs Jeener et Brachet, 6041 Gosselies, Belgium
- Center for Microscopy and Molecular Imaging (CMMI), Université Libre de Bruxelles, 12, Rue des Profs Jeener et Brachet, 6041 Gosselies, Belgium
| | - Derek P. Nolan
- School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland
| | - Etienne Pays
- Laboratory of Molecular Parasitology, IBMM, Université Libre de Bruxelles, 12, rue des professeurs Jeener et Brachet, 6041 Gosselies, Belgium
| |
Collapse
|
13
|
Barry P, Lee A, Charman S, Cosgriff R, Jones A. P067 Using a national cystic fibrosis Registry to explore longitudinal outcome measures at an adult cystic fibrosis centre in comparison with other centres. J Cyst Fibros 2020. [DOI: 10.1016/s1569-1993(20)30403-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Hogue C, Kuzel T, Borgia J, Marwaha G, Bonomi P, Fidler M, Batus M, Wang D, Barry P. P2.04-69 Impact of Antibiotic Usage on Survival During Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1574] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
15
|
Scott J, Jokl E, Pritchett J, Piper-Hanley K, Barry P, Athwal V, Jones A. P309 FibroScan improves diagnosis of Cystic Fibrosis-Related Liver Disease. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30602-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
16
|
Green H, Smith M, Edwards G, Barry P, Brennan A, Bright-Thomas R, Horsley A, Webb K, Jones A. P158 A single centre experience of Mycobacterium abscessus culture, treatment and eradication data in adults with cystic fibrosis. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30452-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Fordyce C, Langman H, Driver K, Johnson S, Barry P, Green H, Cullen M, Smith M, Kenna D, Jones A. P395 An audit of cleaning regimens reported by patients and contamination of their inhalation devices. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30687-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
18
|
Chowdhary M, Lee A, Gao S, Barry P, Diaz R, Bagadiya N, Park H, Yu J, Wilson L, Moran M, Higgins S, Knowlton C, Patel K. PV-0045 Is proton therapy a "pro" for breast cancer? A comparison of proton vs. non-proton RT using the NCDB. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30465-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
19
|
Muscara F, Christaki G, Richardson C, O'Connell R, Padmanabhan P, Warwick J, Lee Y, Smith I, Nerurkar A, Osin P, Krupa K, Rusby J, Roche N, Gui G, MacNeil F, Barry P. Abstract P3-03-14: Clinical utility of one-step nucleic acid amplification (OSNA) in axillary surgery after neoadjuvant chemotherapy (NAC). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-03-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
NAC has been used for downsizing of the tumour in breast and axilla to allow more conservative surgery. In the NAC setting, intraoperative assessment of sentinel lymph node(s) (SLN) is still considered necessary1. Current awareness of the prognostic value for axillary nodal down-staging has renewed interest in analysis of SLN post-NAC.
In this study we want to examine the clinical utility of OSNA (based on CK19 mRNA detection) as a method of intra-operative analysis of SLN to assist real-time decision-making for axillary surgery post-NAC in early breast cancer (EBC).
Methods
Retrospective analysis of prospective data on 399 consecutive patients with EBC who received NAC followed by breast surgery with SLN biopsy (408 axillae) and assessment by OSNA, from September 2011 to January 2018 at the Royal Marsden Hospital (UK). OSNA readouts from the Sysmex RD-100i were collected separate to and blinded from clinico-pathological data. A negative or benign pre-treatment axillary ultrasound scan or indeterminate ultrasound with negative or benign axillary cytology/histology prior to NAC was considered cN0. Univariate analysis (significance at p<0.05) was used to identify risk of recurrence. Patients had a median (mean) follow up of 32.5 (36) months.
Results
The median age at diagnosis was 49 years, median BMI 26, 41 EBC (10%) were screen-detected, 292 (72%) were grade 3 and the most frequent phenotype was receptor triple negative (n=132, 32%).
Of 408 axillae, 248 (60%) were initially cN0, of which 113 (46%) had a pathological complete response (pCR) in the breast. SLN in 54 (22%) cN0 patients were positive on OSNA, of which only 6 (9%) had further involved axillary nodes all 6 of which were ER+ Her2-.
The remaining 160 (40%) axillae were cN1 of which 87 (54%) had conversion to ypN0 including 55 (34%) with both ypT0ypN0.
Axillary lymphadenectomy (AL) was performed in 79 (19%) patients overall, of which n=22 (28%) were cN0 and 57 (72%) were cN1. Of these, 30 (53%) of the cN1 and 6 of 22 (45%) of cN0 had at least 1 additional positive AL node.
Overall 59 (14.4%) patients relapsed. A significantly worse rate of relapse was observed in cN1 compared to cN0 patients (37/159 (23.3%) versus 22/244 (9%), p<0.001). Combined pCR of both breast and axilla (in cN1, n=54) was associated with a significantly reduced risk of relapse and death (p<0.001) compared to those without pCR of either breast or axilla (n=62). Of the latter 18 (29%) relapsed (including 10 deaths).
The mean of both the single highest node tumour load (and total nodal tumour load), as measured by CK19mRNA copies/ul on OSNA, were significantly higher at 90,000 (98,300) for those who relapsed versus 23,100 (25,100) for those without relapse (p=0.027).
Conclusions
The OSNA assay is an accurate tool for axillary SLN analysis in patients after NAC and was helpful in intra-operative axillary management. OSNA reduces the need for a second surgery for AL in 20% of breast cancer patients with a positive-SLN after NAC and might offer additional prognostic value.
Reference
1. NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Breast Cancer.2016.Version 2.2016.
Citation Format: Muscara F, Christaki G, Richardson C, O'Connell R, Padmanabhan P, Warwick J, Lee Y, Smith I, Nerurkar A, Osin P, Krupa K, Rusby J, Roche N, Gui G, MacNeil F, Barry P. Clinical utility of one-step nucleic acid amplification (OSNA) in axillary surgery after neoadjuvant chemotherapy (NAC) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-03-14.
Collapse
Affiliation(s)
- F Muscara
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - G Christaki
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - C Richardson
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - R O'Connell
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - P Padmanabhan
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - J Warwick
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - Y Lee
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - I Smith
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - A Nerurkar
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - P Osin
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - K Krupa
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - J Rusby
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - N Roche
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - G Gui
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - F MacNeil
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - P Barry
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| |
Collapse
|
20
|
Dowsett M, Jacobs S, Johnston S, Bliss J, Wheatley D, Holcombe C, Stein R, McIntosh S, Barry P, Dolling D, Snowdon C, Perry S, Batten L, Dodson A, Martins V, Modi A, Cornman C, Puhalla S, Wolmark N, Julian T, Pogue-Geile K, Robidoux A, Provencher L, Boileau JF, Shalaby I, Thirlwell M, Fisher K, Huang Bartlett C, Koehler M, Osborne K, Rimawi M. Abstract GS3-02: PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-gs3-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: CDK4/6 inhibitors, such as palbociclib, are used to treat ER+ metastatic breast cancer in combination with endocrine therapy with trials ongoing in patients with primary disease. No biomarkers exist to identify those who do/do not benefit from added CDK4/6 inhibition. PALLET is an investigator-initiated/led phase II randomized trial collaboration between UK and NSABP investigators evaluating the biological and clinical effects of palbociclib with letrozole combination as neoadjuvant therapy.
Methods: Postmenopausal women with ER+ primary breast cancer and tumors >2.0cm (ultrasound) were randomized to one of 4 treatment groups (3:2:2:2 ratio): Group A: letrozole (2.5mg/d) for 14 weeks; Group B: letrozole for 2 weeks followed by letrozole + palbociclib to 14 weeks; Group C: palbociclib for 2 weeks followed by letrozole + palbociclib to 14 weeks; Group D: letrozole + palbociclib for 14 weeks. Palbociclib was given 125mg/d PO on a 21 days on, 7 days off schedule. Post-14 week treatment was at the discretion of the treating clinician including letrozole until surgery. Core-cut biopsies were taken at baseline, 2 weeks and 14 weeks. Co-primary endpoints for letrozole alone vs palbociclib groups (Group A vs Groups B+C+D) were: (i) change in Ki67 (IHC) between baseline and 14 weeks (log-fold change, Mann-Whitney test); (ii) clinical response (ultrasound) after 14 weeks (4 group, ordinal, Mann-Whitney test). Complete cell-cycle arrest (CCCA) (Ki67≤2.7%) was analyzed using a logistic regression model adjusting for recruitment region. Pre-specified exploratory biomarkers included c-PARP (apoptosis).
Results: 307 patients were recruited between 27 Feb 2015 and 08 Mar 2018; 103 were randomized to letrozole alone and 204 to letrozole + palbociclib. 279 (90.9%) patients were evaluable for 14 week clinical response. Clinical response was not significantly different between letrozole vs letrozole + palbociclib groups [(p=0.20; CR+PR 49.5% (46/93) vs 54.3% (101/186) and PD 5.4% (5/93) vs 3.2% (6/186)] nor was the small proportion of patients with pathological CR (1/87, 1.1% vs 6/180, 3.3%; p=0.43). 190 (61.9%) patients were evaluable for 14 week change in Ki67. The median log-fold change in Ki67 was greater with letrozole + palbociclib vs letrozole alone (-4.1 vs -2.2; p<0.001) corresponding to a geometric mean change of -97.4% vs -88.5%. Similarly, a greater proportion of patients who received letrozole + palbociclib achieved CCCA (90% vs 59%, p<0.001). 146 (47.6%) patients were evaluable for c-PARP and the log-fold change (suppression) was greater with letrozole + palbociclib vs letrozole alone (-0.80 vs -0.42; p=0.003) corresponding to a geometric mean change of -56.8% vs -31.4%. Other biomarkers of response / resistance are being evaluated. A higher proportion of patients had a grade ≥3 toxicity on letrozole + palbociclib than letrozole alone (49.8% vs 17.0%; p<0.001) mainly due to asymptomatic neutropenia.
Conclusion: Adding palbociclib to letrozole markedly enhanced the suppression of malignant cell proliferation as assessed by Ki67 but did not substantially increase the clinical response of primary ER+ breast cancer over a 14-week period. Concurrent reductions in cell death may have reduced the speed of tumor shrinkage.
Citation Format: Dowsett M, Jacobs S, Johnston S, Bliss J, Wheatley D, Holcombe C, Stein R, McIntosh S, Barry P, Dolling D, Snowdon C, Perry S, Batten L, Dodson A, Martins V, Modi A, Cornman C, Puhalla S, Wolmark N, Julian T, Pogue-Geile K, Robidoux A, Provencher L, Boileau JF, Shalaby I, Thirlwell M, Fisher K, Huang Bartlett C, Koehler M, Osborne K, Rimawi M. PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS3-02.
Collapse
Affiliation(s)
- M Dowsett
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - S Jacobs
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - S Johnston
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - J Bliss
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - D Wheatley
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - C Holcombe
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - R Stein
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - S McIntosh
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - P Barry
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - D Dolling
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - C Snowdon
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - S Perry
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - L Batten
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - A Dodson
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - V Martins
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - A Modi
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - C Cornman
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - S Puhalla
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - N Wolmark
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - T Julian
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - K Pogue-Geile
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - A Robidoux
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - L Provencher
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - JF Boileau
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - I Shalaby
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - M Thirlwell
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - K Fisher
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - C Huang Bartlett
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - M Koehler
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - K Osborne
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - M Rimawi
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| |
Collapse
|
21
|
Barry P. Pre-pectoral Breast Reconstruction - An early experience with acellular peritoneal mesh. Eur J Surg Oncol 2019. [DOI: 10.1016/j.ejso.2018.10.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
22
|
Bell S, De Boeck K, Drevinek P, Plant B, Barry P, Elborn S, de Kock H, Loyau S, Muller K, Vandebriel L, Kanters D, Van de Steen O, Conrath K. WS01.4 GLPG2222 in subjects with cystic fibrosis and the F508del/Class III mutation on stable treatment with ivacaftor: results from a phase II study (ALBATROSS). J Cyst Fibros 2018. [DOI: 10.1016/s1569-1993(18)30122-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
23
|
Magnani L, Pruneri G, Patten DK, Corleone G, Győrffy B, Erdős E, Saiakhova A, Goddard K, Vingiani A, Shousha S, Pongor LS, Hadjiminas DJ, Schiavon G, Barry P, Palmieri C, Coombes RC, Scacheri P. Abstract P2-04-01: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-04-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- L Magnani
- Imperial College London, United Kingdom; Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Italy; 2MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Hungary; University of Debrecen, Hungary; Case Comprehensive Cancer Center, Case Western Reserve University; Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom; European Institute of Oncology, Italy; Imperial, College London, Charing Cross, United Kingdom; Translational Science, IMED Oncology, AstraZeneca, Cambridge, United Kingdom; The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, United Kingdom; Institute of Translational Medicine University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, United Kingdom
| | - G Pruneri
- Imperial College London, United Kingdom; Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Italy; 2MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Hungary; University of Debrecen, Hungary; Case Comprehensive Cancer Center, Case Western Reserve University; Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom; European Institute of Oncology, Italy; Imperial, College London, Charing Cross, United Kingdom; Translational Science, IMED Oncology, AstraZeneca, Cambridge, United Kingdom; The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, United Kingdom; Institute of Translational Medicine University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, United Kingdom
| | - DK Patten
- Imperial College London, United Kingdom; Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Italy; 2MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Hungary; University of Debrecen, Hungary; Case Comprehensive Cancer Center, Case Western Reserve University; Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom; European Institute of Oncology, Italy; Imperial, College London, Charing Cross, United Kingdom; Translational Science, IMED Oncology, AstraZeneca, Cambridge, United Kingdom; The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, United Kingdom; Institute of Translational Medicine University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, United Kingdom
| | - G Corleone
- Imperial College London, United Kingdom; Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Italy; 2MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Hungary; University of Debrecen, Hungary; Case Comprehensive Cancer Center, Case Western Reserve University; Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom; European Institute of Oncology, Italy; Imperial, College London, Charing Cross, United Kingdom; Translational Science, IMED Oncology, AstraZeneca, Cambridge, United Kingdom; The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, United Kingdom; Institute of Translational Medicine University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, United Kingdom
| | - B Győrffy
- Imperial College London, United Kingdom; Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Italy; 2MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Hungary; University of Debrecen, Hungary; Case Comprehensive Cancer Center, Case Western Reserve University; Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom; European Institute of Oncology, Italy; Imperial, College London, Charing Cross, United Kingdom; Translational Science, IMED Oncology, AstraZeneca, Cambridge, United Kingdom; The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, United Kingdom; Institute of Translational Medicine University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, United Kingdom
| | - E Erdős
- Imperial College London, United Kingdom; Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Italy; 2MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Hungary; University of Debrecen, Hungary; Case Comprehensive Cancer Center, Case Western Reserve University; Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom; European Institute of Oncology, Italy; Imperial, College London, Charing Cross, United Kingdom; Translational Science, IMED Oncology, AstraZeneca, Cambridge, United Kingdom; The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, United Kingdom; Institute of Translational Medicine University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, United Kingdom
| | - A Saiakhova
- Imperial College London, United Kingdom; Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Italy; 2MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Hungary; University of Debrecen, Hungary; Case Comprehensive Cancer Center, Case Western Reserve University; Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom; European Institute of Oncology, Italy; Imperial, College London, Charing Cross, United Kingdom; Translational Science, IMED Oncology, AstraZeneca, Cambridge, United Kingdom; The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, United Kingdom; Institute of Translational Medicine University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, United Kingdom
| | - K Goddard
- Imperial College London, United Kingdom; Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Italy; 2MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Hungary; University of Debrecen, Hungary; Case Comprehensive Cancer Center, Case Western Reserve University; Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom; European Institute of Oncology, Italy; Imperial, College London, Charing Cross, United Kingdom; Translational Science, IMED Oncology, AstraZeneca, Cambridge, United Kingdom; The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, United Kingdom; Institute of Translational Medicine University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, United Kingdom
| | - A Vingiani
- Imperial College London, United Kingdom; Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Italy; 2MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Hungary; University of Debrecen, Hungary; Case Comprehensive Cancer Center, Case Western Reserve University; Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom; European Institute of Oncology, Italy; Imperial, College London, Charing Cross, United Kingdom; Translational Science, IMED Oncology, AstraZeneca, Cambridge, United Kingdom; The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, United Kingdom; Institute of Translational Medicine University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, United Kingdom
| | - S Shousha
- Imperial College London, United Kingdom; Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Italy; 2MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Hungary; University of Debrecen, Hungary; Case Comprehensive Cancer Center, Case Western Reserve University; Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom; European Institute of Oncology, Italy; Imperial, College London, Charing Cross, United Kingdom; Translational Science, IMED Oncology, AstraZeneca, Cambridge, United Kingdom; The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, United Kingdom; Institute of Translational Medicine University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, United Kingdom
| | - LS Pongor
- Imperial College London, United Kingdom; Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Italy; 2MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Hungary; University of Debrecen, Hungary; Case Comprehensive Cancer Center, Case Western Reserve University; Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom; European Institute of Oncology, Italy; Imperial, College London, Charing Cross, United Kingdom; Translational Science, IMED Oncology, AstraZeneca, Cambridge, United Kingdom; The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, United Kingdom; Institute of Translational Medicine University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, United Kingdom
| | - DJ Hadjiminas
- Imperial College London, United Kingdom; Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Italy; 2MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Hungary; University of Debrecen, Hungary; Case Comprehensive Cancer Center, Case Western Reserve University; Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom; European Institute of Oncology, Italy; Imperial, College London, Charing Cross, United Kingdom; Translational Science, IMED Oncology, AstraZeneca, Cambridge, United Kingdom; The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, United Kingdom; Institute of Translational Medicine University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, United Kingdom
| | - G Schiavon
- Imperial College London, United Kingdom; Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Italy; 2MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Hungary; University of Debrecen, Hungary; Case Comprehensive Cancer Center, Case Western Reserve University; Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom; European Institute of Oncology, Italy; Imperial, College London, Charing Cross, United Kingdom; Translational Science, IMED Oncology, AstraZeneca, Cambridge, United Kingdom; The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, United Kingdom; Institute of Translational Medicine University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, United Kingdom
| | - P Barry
- Imperial College London, United Kingdom; Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Italy; 2MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Hungary; University of Debrecen, Hungary; Case Comprehensive Cancer Center, Case Western Reserve University; Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom; European Institute of Oncology, Italy; Imperial, College London, Charing Cross, United Kingdom; Translational Science, IMED Oncology, AstraZeneca, Cambridge, United Kingdom; The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, United Kingdom; Institute of Translational Medicine University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, United Kingdom
| | - C Palmieri
- Imperial College London, United Kingdom; Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Italy; 2MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Hungary; University of Debrecen, Hungary; Case Comprehensive Cancer Center, Case Western Reserve University; Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom; European Institute of Oncology, Italy; Imperial, College London, Charing Cross, United Kingdom; Translational Science, IMED Oncology, AstraZeneca, Cambridge, United Kingdom; The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, United Kingdom; Institute of Translational Medicine University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, United Kingdom
| | - RC Coombes
- Imperial College London, United Kingdom; Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Italy; 2MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Hungary; University of Debrecen, Hungary; Case Comprehensive Cancer Center, Case Western Reserve University; Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom; European Institute of Oncology, Italy; Imperial, College London, Charing Cross, United Kingdom; Translational Science, IMED Oncology, AstraZeneca, Cambridge, United Kingdom; The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, United Kingdom; Institute of Translational Medicine University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, United Kingdom
| | - P Scacheri
- Imperial College London, United Kingdom; Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Italy; 2MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Hungary; University of Debrecen, Hungary; Case Comprehensive Cancer Center, Case Western Reserve University; Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom; European Institute of Oncology, Italy; Imperial, College London, Charing Cross, United Kingdom; Translational Science, IMED Oncology, AstraZeneca, Cambridge, United Kingdom; The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, United Kingdom; Institute of Translational Medicine University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, United Kingdom
| |
Collapse
|
24
|
Kearney GD, Allen DL, Balanay JAG, Barry P. A Descriptive Study of Body Pain and Work-Related Musculoskeletal Disorders Among Latino Farmworkers Working on Sweet Potato Farms in Eastern North Carolina. J Agromedicine 2017; 21:234-43. [PMID: 27081751 DOI: 10.1080/1059924x.2016.1178613] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Agricultural work is a physically demanding occupation. The purpose of this project was to describe the prevalence of work-related musculoskeletal disorders (WMSDs) and self-reported pain among Latino farmworkers who work extensively hand harvesting sweet potatoes. Data were obtained from a cross-sectional survey of farmworkers (N = 120) in eastern North Carolina. Univariate and bivariate analyses were used to describe personal, work characteristics, and self-reported pain associated with musculoskeletal injuries. Overall, 79% of farmworkers reported any type of pain or discomfort. The highest reported areas of pain were in the back (66%) and shoulder areas (31%). Younger participants experienced more shoulder pain (P = .04) than older workers, and working more than 5 years as a farmworker was significantly associated with back pain (P = .01). Interventions aimed at administrative and engineering controls for reducing risk factors that contribute to WMSDs are warranted.
Collapse
Affiliation(s)
- Gregory D Kearney
- a Department of Public Health , Brody School of Medicine, East Carolina University , Greenville , North Carolina , USA
| | - Daniel L Allen
- a Department of Public Health , Brody School of Medicine, East Carolina University , Greenville , North Carolina , USA
| | - Jo Anne G Balanay
- b Environmental Health Sciences Program, Department of Health Education and Promotion , College of Health and Human Performance, East Carolina University , Greenville , North Carolina , USA
| | - Paul Barry
- a Department of Public Health , Brody School of Medicine, East Carolina University , Greenville , North Carolina , USA
| |
Collapse
|
25
|
O'Connell R, Rusby J, Stamp G, Conway A, Roche N, Barry P, Khabra K, Bonomi R, Rapisarda I, della Rovere G. Long term results of treatment of breast cancer without axillary surgery – Predicting a SOUND approach? Eur J Surg Oncol 2016; 42:942-8. [DOI: 10.1016/j.ejso.2016.03.027] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2016] [Accepted: 03/29/2016] [Indexed: 12/01/2022] Open
|
26
|
Barry P. Increased Uptake of Intracameral Antibiotic Prophylaxis in Europe. Acta Ophthalmol 2015. [DOI: 10.1111/j.1755-3768.2015.0588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- P. Barry
- Ophthalmology; St Vincent's University Hospital Group; Dublin Ireland
| |
Collapse
|
27
|
Browning S, Omal H, Barry P, Ramaswamykanive H. Package inserts: to believe or not to believe. Anaesth Intensive Care 2015; 43:280. [PMID: 25735703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
|
28
|
Green H, Bright-Thomas R, Barry P, Horsley A, Mutton K, Jones A. P201 Pneumocystis Jirovecii Prevalence In A Large Uk Adult Cystic Fibrosis Centre. Thorax 2014. [DOI: 10.1136/thoraxjnl-2014-206260.330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
29
|
Green H, Bright-Thomas R, Barry P, Woodford N, Isalska B, Horsley A, Kenna D, Jones A. P199 Molecular Analysis Demonstrates Shared Strains Of Mycobacterium Abscessus Isolates In Cystic Fibrosis Patients Attending A Single Centre. Thorax 2014. [DOI: 10.1136/thoraxjnl-2014-206260.328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
30
|
Green H, Barry P, Paisey C, Smith A, Flight W, Marchesi J, Jones A, Horsley A, Mahenthiralingam E. P196 The Effect Of Ivacaftor Therapy On The Microbial Diversity Of Cystic Fibrosis Lung Infection. Thorax 2014. [DOI: 10.1136/thoraxjnl-2014-206260.325] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
31
|
|
32
|
Abstract
The target sites of three herbicides which inhibit carotenoid biosynthesis have been characterized using HPLC analysis of pigment extracts from two higher plant systems, carrot cell suspension cultures and barley seedlings. Diflufenican causes an accumulation of phytoene and phytofluene. Dichlormate causes accumulation of phytoene, phytofluene, ξ-carotene, neurosporene and β-zeacarotene. Amitrole causes accumulation of phytoene, phytofluene, β- γ- and δ-carotenes and lycopene. Significant differences in the geometric and hydroxylated natures of the accumulated precursors occurred between the carrot cell and dark- and light-grown barley. These differences are discussed with respect to both the target sites of the three carotenogenic herbicides and the biosynthetic pathway leading to carotenoid biosynthesis in higher plants.
Collapse
Affiliation(s)
- Paul Barry
- Plant Biochemistry Research Department, Rhône-Poulenc A griculture, Fyfield Road, Ongar, Essex, CM 50 HW, U.K
| | - Ken E. Pallett
- Plant Biochemistry Research Department, Rhône-Poulenc A griculture, Fyfield Road, Ongar, Essex, CM 50 HW, U.K
| |
Collapse
|
33
|
Green H, Bright-Thomas R, Barry P, Horsley A, Mutton K, Jones A. 158 Prevalence of Pneumocystis jirovecii in a cross section of patients attending a large UK adult cystic fibrosis centre. J Cyst Fibros 2014. [DOI: 10.1016/s1569-1993(14)60294-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
34
|
Green H, Bright-Thomas R, Barry P, Horsley A, Isalska B, Woodford N, Kenna D, Jones A. 160 Molecular profiling demonstrates clustering of Mycobacterium abscessus isolates in CF patients from a single centre. J Cyst Fibros 2014. [DOI: 10.1016/s1569-1993(14)60296-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
35
|
Rusby JE, Agabiti E, Waheed S, Barry P, Roche N, Allum W, Gui G, MacNeill F, Christaki G, Osin P, Nerurkar A. Abstract P1-01-11: Is OSNA mRNA copy number in sentinel lymph node biopsy predictive of further disease in the axilla? Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-01-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Intra-operative assessment of sentinel nodes (SLNs) allows immediate completion axillary dissection (cALND) in breast cancer patients. Molecular assessment such as one-step nucleic acid amplication (OSNA) promises greater sensitivity and provides a more accurate quantitative assessment than traditional methods.
Our unit policy is to proceed to cALND in patients with macrometastases but not for micrometastases. However, evidence of upstaging has led us to seek to raise the threshold for proceeding to cALND. The CK19 mRNA copy number is an expression of the metastatic burden in the SLN and may be related to the presence of additional disease in the cALND. Since the original copy number threshold between micro (250–5000 copies/microliter) and macrometastasis (>5000 copies/microliter) was based on few patients and serial pathological sections, we investigated the mRNA copy number in patients with and without additional disease in the cALND.
Methods: All patients in our unit undergo pre-operative axillary ultrasound with fine needle aspiration cytology of any suspicious nodes. Those with malignant cytology proceed directly to ALND. Radiologically and cytologically node negative patients undergo sentinel lymph node biopsy (SLNB) and OSNA. Electronic records of consecutive patients with invasive breast cancer undergoing SLNB with OSNA from August 2011 to March 2012 were retrospectively reviewed. Two parameters of mRNA copy number were examined: Copy number of the highest copy number SLN and the summed copy numbers of all positive SLNs. Their relationship to the presence of further disease in the axilla was examined using Student's t test.
Results: Of 201 SLNBs, 45 (22%) had macrometastasis-positive OSNA and therefore underwent cALND (1 patient declined). Twenty patients (45%) had no further positive nodes (a negative cALND) with a total axillary metastatic burden of 1–2 in 11–27 nodes. Twenty four (55%) showed further disease (a positive cALND) with a burden of 2–20 in 9–30 nodes, including the SLNs.
There was no significant difference in tumour size or grade between patients with additional positive nodes in the cALND compared with those with no further disease.
There was no significant difference in the copy number of the highest copy number positive SLN (p = 0.44) or in the summed copy number of all positive SLNs (p = 0.36) between the cALND positive and negative groups.
Conclusion: OSNA CK19 mRNA copy number does not correlate with the cALND metastatic burden. Therefore, raising the copy number threshold may be too simplistic as a method to better select patients with high probability of a positive cALND. A predictive model will be derived based on multivariate analysis of the larger patient population (>400 patients) that will have undergone SLNB with OSNA by the time of SABCS.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-01-11.
Collapse
Affiliation(s)
- JE Rusby
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - E Agabiti
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - S Waheed
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - P Barry
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - N Roche
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - W Allum
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - G Gui
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - F MacNeill
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - G Christaki
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - P Osin
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - A Nerurkar
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| |
Collapse
|
36
|
Licitri O, Liet S, Laime D, Barry P, Jacquand M, Dutheil F, Chamoux A. Comportements de consommation potentiellement addictogène dans une population de salariés du Puy-de-Dôme et de la Haute-Loire en 2011. ARCH MAL PROF ENVIRO 2012. [DOI: 10.1016/j.admp.2012.03.467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
Barry P. Conferences and events of interest. Inj Prev 2010. [DOI: 10.1136/ip.2010.031021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
38
|
Willis D, Barry P. Audiovisual Interventions to Reduce the Use of General Anaesthesia with Paediatric Patients during Radiation Therapy. J Med Imaging Radiat Oncol 2010; 54:249-55. [DOI: 10.1111/j.1754-9485.2010.02165.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
39
|
Hartigan I, Cooke J, Barry P, O’Connor M, O’Mahony D. The incidence of acute stroke emergency admissions in an Irish teaching hospital. Ir J Med Sci 2010; 179:67-71. [DOI: 10.1007/s11845-009-0379-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2008] [Accepted: 06/08/2009] [Indexed: 11/24/2022]
|
40
|
Ryan C, O'Mahony D, Kennedy J, Weedle P, Barry P, Gallagher P, Byrne S. Appropriate prescribing in the elderly: an investigation of two screening tools, Beers criteria considering diagnosis and independent of diagnosis and improved prescribing in the elderly tool to identify inappropriate use of medicines in the elderly in primary care in Ireland. J Clin Pharm Ther 2009; 34:369-76. [PMID: 19583669 DOI: 10.1111/j.1365-2710.2008.01007.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Elderly patients are particularly vulnerable to inappropriate prescribing, with increased risk of adverse drug reactions and consequently higher rates of morbidity and mortality. A large proportion of inappropriate prescribing is preventable by adherence to prescribing guidelines, suitable monitoring and regular medication review. As a result, screening tools have been developed to help clinicians improve their prescribing. OBJECTIVES To compare identification rates of inappropriate prescribing in elderly patients in primary care using two validated screening tools: Beers' criteria and improved prescribing in the elderly tool (IPET); to calculate the net ingredient cost (NIC) per month (euro) of the potentially inappropriate medicines in this population of patients. METHOD A consecutive cohort of 500 patients 65 years of age and over were recruited prospectively from primary care over a 6 month period in a provincial town in Ireland. Patients' medical records (electronic and paper) were screened and all relevant information concerning current illnesses and medications was recorded on a standardized data collection form to which Beers' criteria [considering diagnosis (CD) and independent of diagnosis (ID)] and IPET tools were applied. The NIC was calculated from an edition of the Irish monthly index of medical specialities published concurrently with the data collection. RESULTS Beers' criteria identified a total of 69 medicines that were prescribed inappropriately (eight CD and 61 ID) in 65 patients (13%), costing euro824.88 per month while IPET identified 63 potentially inappropriate medicines in 52 (10.4%) patients costing euro381.28 per month. CONCLUSIONS Potentially inappropriate medications are prescribed in a significant proportion of elderly people in primary care, with significant economic implications.
Collapse
Affiliation(s)
- C Ryan
- Pharmaceutical Care Research Group, School of Pharmacy, University College Cork, Cork, Ireland
| | | | | | | | | | | | | |
Collapse
|
41
|
Robison SM, Kljakovic M, Barry P. SO04�MANAGEMENT OF SUSPICIOUS MELANOCYTIC LESIONS IN GENERAL PRACTICE. ANZ J Surg 2009. [DOI: 10.1111/j.1445-2197.2009.04932_4.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
42
|
Kirwan RP, Abdalla M, Hogan A, Tubridy N, Barry P, Power W. Superior orbital fissure syndrome in herpes zoster ophthalmicus. Ir J Med Sci 2009; 178:355-8. [PMID: 19139952 DOI: 10.1007/s11845-008-0266-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2008] [Accepted: 11/19/2008] [Indexed: 11/27/2022]
Abstract
AIM To report a case of superior orbital fissure syndrome (SOFS) in a patient with herpes zoster ophthalmicus (HZO). MATERIALS AND METHODS A case report. RESULTS A 71-year-old male with HZO presented acutely to accident and emergency complaining of right vision loss, double vision and drowsiness. The right visual acuity was counting fingers. There was no relative afferent pupillary defect. He had interstitial keratitis, ptosis, proptosis and total ophthalmoplaegia. The signs indicated HZO complicated by SOFS. Brain imaging and lumbar puncture confirmed the diagnosis of varicella zoster encephalitis. Systemic acyclovir and prednisolone led to recovery of visual acuity and ocular motility in addition to resolution of his proptosis and ptosis. CONCLUSION SOFS is a rare complication of herpes zoster infection. With the appropriate treatment and follow-up, patients may be reassured that recovery of their visual acuity and ocular motility will occur.
Collapse
Affiliation(s)
- R P Kirwan
- Department of Ophthalmic Surgery, St Vincent's University Hospital, Dublin 4, Ireland.
| | | | | | | | | | | |
Collapse
|
43
|
Vind AB, Andersen HE, Schwarz P, Skalska A, Salakowski A, Dubiel M, Fedak D, Grodzicki T, Annweiler C, Schott AM, Fantino B, Berrut G, Herrmann F, Beauchet O, Engels S, Schroll M, Popescu C, Onose G, Bojan A, van Zutphen M, Bemelmans W, de Groot L, Rea IM, Henry M, Young IS, Evans AE, Kee F, Ambien CF, Whitehead AS, Ryzhak G, Khavinson V, Kozlov L, Povoroznyuk V, Kivela SL, Nielsen DS, Nielsen W, Knold B, Ryg J, Nissen N, Brixen K, Bjorkman M, Sorva A, Tilvis R, Kannegaard PN, Jung A, Simonsen F, Sanders S, Puustinen J, Nurminen J, Lopponen M, Vahlberg T, Isoaho R, Kivela SL, Hayashi T, Ina K, Nomura H, Iguchi A, Rea IM, Henry M, Evans AE, Tiret L, Poire O, Cambien F, Pautex S, Notaridis G, Derame L, Zulian G, Ungar A, Fedeli A, Zanieri S, Pecchioni S, Belladonna M, Lambertucci L, Lotti E, Pepe G, Bambi A, Morrione A, Masotti G, Marchionni M, Mazzella F, Napoli C, Vitale DF, Viati L, Longobardi G, Lucchetti G, Abete P, Rengo F, Pautex S, Herrmann F, le Lous P, Gold G, Lihavainen K, Sipila S, Rantanenv T, Hartikainen S, Biswas S, Willicombe S, Myint P, Rashidi F, Gillain D, Van Den Noortgate N, Van Der Mark S, Petersen H, Sejtved B, Melton R, Mur AZ, Catevilla AZ, Boix LA, Jordá P, Ranhoff AH, González E, Florian J, Bueso P, Nuotio M, Luukkaala T, Tammela TLJ, Jylhä M, De Antonio García MP, De Abia PG, Bergua AA, Mowinckel P, Orozco MC, Ruiz MC, Verdejo-Bravo C, De Saint-Hubert M, Divoy C, Schoevaerdts D, Swine C, Heppner HJ, Sieber C, Bertsch T, Volpato S, Heppner HJ, Sieber C, Heppner HJ, Sieber C, Heppner HJ, Sieber C, Michael A, Scoyni R, Trani I, Schiaffini C, Sioulis F, Felli B, Aiello L, Belli P, Pacitti MT, Morelli A, D’imperio M, Falanga A, Carratelli D, Morocutti M, Kitisomprayoonkul W, Guerra G, Promsopa K, Chaiwanichsiri D, Ochiana V, Ghorghe S, Popescu G, Tekeira A, Khayat M, Povoroznyuk V, Grygoryeva N, Dzerovych N, Cavalieri M, Karasevskaya T, Mowe M, Skalska A, Fedak D, Grodzicki T, Soda K, Kano Y, Shingo T, Konishi F, Kawakami M, Maraldi C, Ulger Z, Cankurtaran M, Halil M, Yavuz BB, Orhan B, Dede D, Kavas GO, Kocaturk PA, Akyol O, Ariogul S, Guralnik JM, Pircalabu R, Hnidei R, Morosanu B, Rada C, Ionescu C, Yamada M, Kasagi F, Tatsukawa Y, Sasaki H, Alcalde P, Fellin R, Luque M, García M, Ariño S, Carmona G, Rizzoli R, Ammann P, Pressel E, Eddy C, Lilja A, Rønholt F, Pilotto A, Danbaek L, Van der Mark S, Ammann P, Kream B, Rosen C, Rizzoli R, Dubois-Ferrière V, Rizzoli R, Ammann P, Ditloto G, Addante F, Hussain W, Farrelly E, Marsden P, Brewer L, Fallon C, Murphy S, Jørgensen NR, Husted LB, Tofteng CL, Jensen JEB, Franceschi M, Eiken P, Nissen N, Langdahl BL, Schwarz P, Mcintosh S, Lacey E, Carvell C, Povoroznyuk V, Grygoryeva N, Kreslov Y, Leandro G, Dzerovych N, Ozerov I, Vayda V, Povoroznyuk V, Dzerovych N, Karasevskaya T, Povoroznyuk V, Vayda V, Böhmdorfer B, Frühwald T, D’onofrio G, Sommeregger U, Muster U, Böhmdorfer B, Frühwald T, Oeser B, Sommeregger U, Muster U, Cho C, Yoo B, Oh J, Corritore M, Cho K, Lee H, Clemmensen A, Lauridsen M, Nielsen NB, Crome P, Sinclair-Cohen J, Cherubini A, Oristrell J, Hertogh C, Niro V, Szczerbinska K, Lesauskaite V, Prada GI, Clarfield M, Topikova E, Dieppe P, Gallagher P, O’mahony D, Harbig P, Barat I, Scarcelli C, Nielsen PL, Damsgaard EM, Maanen ACDV, Van Marum RJ, Knol W, Van Der Linden CMJ, Jansen PAF, Karlsson M, Berggren AC, Lampela P, Seripa D, Hartikainen S, Lavikainen P, Sulkava R, Huupponen R, Lonergan MT, Coughlan T, ’Neill DO, Lonergan MT, Coughlan T, ’Neill DO, Piccola BD, Krajèík S, Mikus P, Errasquin BM, Cuervo MS, Castellano CS, Silveira ED, Vicedo TB, Cruz-Jentoft AJ, Petrovic M, Cobbaert K, Ferrucci L, Van Der Stichele R, Rajska-Neumann A, Wieczorowska-Tobis K, Ryan C, Kennedy J, O’mahony D, Byrne S, Castellano CS, Fernández CG, Errasquín BM, Bhuachalla BN, Del Rey JM, Peña MIA, Cruz-Jentoft AJ, Trellu LT, Villaneau D, Parel Y, Vogt-Ferrier N, Vanakoski J, Jokinen T, Skippari L, Cotter PE, Iso-Aho M, Guillemard E, Lacoin F, Marcus EL, Caine Y, Kasem H, Gross M, Mukherjee S, Goupal K, Juszczak A, Mhaille BN, Mukherjee S, Romero E, Fernandez C, Ramos M, Gonzalez E, Fuentes M, Mora J, Martin J, Ribera JM, Berg N, Egan A, Vanmeerbeek M, Moreau A, Massart V, Giet D, Bojan A, Onose G, Popescu C, Jönsdóttir AB, Damkjær K, Elkholy K, Kavanagh A, Schroll M, Lindhardt T, Ozdemir L, Gozukara F, Yucel C, Turk R, Akdemir N, Park SMI, Kim DH, Quinlan N, O’connor M, O’neill D, Caffrey N, Lonergan MT, Trainor S, Gowran L, Falconer M, Carroll N, Dwyer C, Coughlan T, O’neill D, O’keeffe ST, Collins DR, Given K, O’neill D, Collins DR, Lund A, Michelet M, Kjeken I, Wyller TB, Sveen U, Meade R, Kristjansson SR, Anniss S, Kachhia A, Hickey A, O’hanlon A, Mcgee H, Shelley E, Horgan F, O’neill D, Osawa A, Maeshima S, Nesbakken A, Sawayama Y, Maeda S, Ohnishi H, Hamada M, Otaguro S, Furusyo N, Hayashi J, Bonet AT, Martorell LV, Truyols AG, Wyller TB, Homar FA, Malberti JC, Huertas P, Wagle J, Farner L, Flekkøy K, Wyller TB, Sandvik L, Eiklid K, Fure B, Bautmans I, Stensrød B, Engedal K, Rnould A, Baron R, Gallais JL, Giniès P, Benmedjahed K, Bartley M, O’neill D, Hürny C, Njemini R, Brack B, Mukherjee S, Chroinin DNI, Farooq SFS, Burke M, Duggan J, Power D, Kyne L, Qvist A, Jørgensen NR, Jansen B, Schwarz P, Sleiman I, Rozzini R, Barbisoni P, Ranhoff A, Trabucchi M, Rønholt F, Jacobsen HN, Rytter L, Seidahamd M, Vierendeels J, Al-Dhahi L, Vigder C, Ben-Israel Y, Kaykov E, Granot E, Raz R, Wulff T, Hendriksen C, Ziccardi P, Cacciatore F, de Backer J, Mazzella F, Viati L, Abete P, Ferrara N, Rengo F, Raschilas F, Adane D, Oziol E, Millot O, Boubakri C, de Waele E, Hemmi P, Tigoulet F, Faucher N, Blain H, Jeandel C, Blain H, Carriere I, Berard C, Favier F, Colvez A, Mets T, Sørensen KI, Brynningsen P, Damsgaard EM, Mehrabian S, Seux ML, Miralles I, Cohen M, Esculier MC, Rigaud AS, Ducasse V, Pilotto A, Lidy C, Samandel S, Geny C, Comte F, Gabelle A, Touchon J, Jeandel C, Morel N, Verny M, Riou B, Addante F, Boddaert J, Marquis C, Greffard S, Dieudonne B, Barrou Z, Boddaert J, Verny M, Bonnet D, Forest A, Verny M, Franceschi M, Boulanger C, Riou B, Malla Z, Boddaert J, Leandro G, D’onofrio G, D’ambrosio LP, Longo MG, Cascavilla L, Paris F, Pazienza AM, Piccola BD, Ferrucci L, Ungar A, Morrione A, Landi A, Caldi F, Maraviglia A, Rafanelli M, Ruffolo E, Chisciotti VM, Masotti G, Marchionni N, van der Velde N, Ziere G, van der Cammen TJM, Hofman B, Stricker BHC, Rodriguez-Pascual C, Moraga AV, Galan EP, Sanchez MJL, Manso AL, Carballido MT, Chiva MTO, Andion JMV, Sierra AL, Pillay I, Saunders J, Cunniffe J, Cooke J, Blot S, Cankurtaran M, Vandijck D, Danneels C, Vandewoude K, Peleman R, Piette AA, Verschraegen G, van den Noortgate N, Vogelaers D, Petrovic M, Skerris A, Kjear P, Cristoffersen J, Shou C, Seest LS, Oestergaard A, Rønholt F, Overgaard K, Donnellan C, Hickey A, Hevey D, O’neill D, van Munster B, Korevaar J, Zwinderman A, Levi M, Wiersinga J, Rooij S, White S, Mahony SO, Bayer A, Juliebo V, Bjøro K, Krogseth M, Ranhoff AH, Wyller TB, Duque AS, Silvestre J, Freitas P, Palma-Reis I, Lopes JP, Martins A, Batalha V, Campos L, Ekstrom H, Elmstahl S, Ivanoff SD, Hayashi T, Ina K, Hirai H, Iguchi A, Lee T, Gallagher P, Hegarty E, Connor MO, Mahony DO, Mkhailova O, Khavinson V, Kozlov L, Chopra NR, Jones DA, Huwez F, Frimann J, Koefoed M, Meyling R, Holm E, Gryglewska B, Sulicka J, Fornal M, Wizner B, Grodzicki T, O’connor L, Lonergan MT, Cogan N, Coughlan T, O’neill D, Collins DR, Prada GI, Fita IG, Prada S, Herghelegiu AM, Datu C, Lonergan MT, Kelleher F, Mcdermott R, Collins DR, Retornaz F, Monette J, Batist G, Monette M, Sourial N, Small D, Caplan S, Wan-Chow-Wah D, Puts MTE, Bergman H, Retornaz F, Sourial N, Seux V, Monette J, Soubeyrand J, Bergman H, Andrei V, Pircalabu R, Lupeanu E, Pena C, Turcu E, Raducanu I, Hnidei A, Morosanu B, Gherasim P, Gradinaru D, Rachita M, Ionescu I, Arino S, Coindreau F, Alcalde P, Serra J, Baldasseroni S, Romboli B, di Serio C, Orso F, Pellerito S, Mannucci E, Colombi C, Bartoli N, Masotti G, Marchionni N, Tarantini F, Barry P, Kinsella S, Twomey C, O’mahony D, Bezerra AW, Popescu G, Azevedo E, Nobrega J, Ghiorghe S, Coindreau F, Serra J, Duems O, Saez I, Clapera G, Arino S, Coindreau F, Serra J, Saez I, Duems O, Clpaera G, Arino S, Jones DA, Chopra NR, Guha K, Clarkson P, Koga T, Furusyo N, Ogawa E, Sawayama Y, Ai M, Otokozawa S, Schaefer EJ, Hayashi J, Lupeanu E, Andrei V, Turcu E, Pircalabu R, Raducanu I, Hnidei R, Morosanu B, Opris S, Ionescu C, Gherasim P, Mellingsaeter M, Wyller TB, Ranhoff AH, Popescu G, Teixeira J, Ghiorghe S, Azevedo E, Teixeira A, Rodriguez-Pascual C, Moraga AV, Carballido MT, Galan EP, Quintela S, Leiros A, Sanchez MJL, Chiva MTO, Sierra AL, Andion JMV, Rios CF, Seabra Pereira MF, Jorge E, Dias R, Verissimo MT, Santos L, Saldanha MH, Sinha S, Dave P, Hussain S, Ayub A, Vilches-Moraga A, Rodriguez-Pascual C, Paredes-Galan E, Leiro-Manso A, Gonzalez-Rios C, Torrente-Carballido M, Vega-Andion JM, Olcoz-Chiva MT, Lopez-Sierra A, Lopez-Sanchez MJ, Narro-Vidal M, Garcia Q, Bozoglu E, Isk AT, Comert B, Doruk H, Sohrt C, Brynningsen P, Damsgaard EM, Kat M, Vreeswijk R, de Jonghe J, van der Ploeg T, van Gool W, Eikelenboom P, Kalisvaart K, Kat M, de Jonghe J, Vreeswijk R, van der Ploeg T, van Gool W, Eikelenboom P, Kalisvaart K, Krogseth M, Juliebø V, Engedal K, Wyller TB, Sharma V, Soiza RL, Ferguson K, Shenkin SD, Seymour DG, Maclullich AMJ, van Munster B, van Breemen M, Moerland P, Speijer D, Rooij S, Hollmann M, Zwinderman A, Korevaar J, Vreeswijk R, Toornvliet A, Honing M, Bakker K, de Man T, de Jonghe JFM, Kalisvaart KJ, Bisschop MM, Sival R, Driesen J, Cappuccio M, Cilesi I, Cirinei E, Ruggiero C, Dell’aquila G, Gasperini B, Patacchini F, Mancioli G, Lauretani F, Bandinelli S, Maggio M, Ferrucci L, Cherubini A, Cruz-Jentoft AJ, de Tena Fontaneda A, Cano LR, Custureri R, Curiale V, Prete C, Cella A, Bonomini C, Barban G, Trasciatti S, Palummeri E, Gasperini B, Ruggiero C, Dell’aquila G, Cirinei E, Patacchini F, Mancioli G, Lauretani F, Bandinelli S, Maggio M, Ferrucci L, Cherubini A, Gold G, Giannakopoulos P, Hermmann F, Bouras C, Kovari E, Halil M, Deniz A, Yavuz B, Yavuz BB, Ülger Z, Cankurtaran M, Isik M, Cankurtaran ES, Aytemir K, Ariogul S, Kanaya K, Abe S, Sakai M, Iwamoto T, Korfitsen T, Moe C, Mecocci P, Mangiaasche F, Costanzi E, Cecchetti R, Rinaldi P, Serafini V, Amici S, Baglioni M, Bastiani P, Lovestone S, Prada GI, Ftta IG, Prada S, Herghelegiu AM, Datu C, Rozzini R, Sleiman I, Barbisoni P, Ranhoff A, Maggi S, Trabucchi M, Shafiei R, Johansen AH, Moe C, Lyngholm-Kxærby P, Kristiansen K, Lestrup C, Lund C, Jones E, Such P, van Puyvelde K, Mets T, Yavuz BB, Yavuz B, Cankurtaran M, Halil M, Ulger Z, Aytemir K, Oto A, Ariogul S, Yavuz BB, Cankurtaran M, Halil M, Ulger Z, Ariogul S, di Bari M, Lattanzio F, Sgadari A, Baccini M, Ercolani S, Rengo F, Senin U, Bernabei R, Marchionni N, Cherubini A, del Bianco L, Lamanna C, Gori F, Monami M, Marchionni N, Masotti G, Mannucci E, Foss CH, Vestbo E, Frøland A, Mogensen CE, Damsgaard EM, Mossello E, Simoni D, Boncinelli M, Gullo M, Mello AM, Lopilato E, Lamanna C, Gori F, Cavallini MC, Marchionni N, Mannucci E, Masotti M, Pena CM, Olaru OG, Pircalabu RM, Raducanu I, Rodriguez-Justo S, Narro-Vidal M, Garcia-Villar E, Rodriguez-Pascual C, Vilches-Moraga A, Olcoz-Chiva MT, Lopez-Sierra A, Vega-Andion JM, Lopez-Sanchez MJ, Torrente-Carballido M, Paredes-Galan E, Vilches-Moraga A, Abbas A, Grue R, Adie K, Fox J, Wileman L, Pattison T, Briggs S, Bhat S, Baker P, Akdemir N, Kapucu SS, Özdemir L, Akkus Y, Balci G, Akyar Y, Cankuran M, Halil M, Kayihan H, Uyanik M, Hazer O, Ariogul S, Cella A, Curiale V, Cuneo G, Fraguglia C, Trasciatti S, Palummeri E, Blundell A, Gordon A, Masud T, Gladman J, Sclater A, Curran V, Kirby B, Forristall J, Sharpe D, Anstey SA, Dawe D, Edwards S, White M, Celik SS, Kapucu SS, Akkuþ Y, Tuna Z, Szczerbinska K, Kijowska V, Mirewska E, Topor-Madry R, Czabanowska K, Maggi S, Franceschi M, Pilotto A, Noale M, Parisi GC, Crepaldi G, Van Gara R, Mcgee H, Winder R, O’neill D, Piers R, Vanden Noortgate N, Schrauwen W, Maertens S, Velghe A, Petrovic M, Benoit D, Cronin H, O’regan C, Kearney P, Moreira A, Kamiya Y, Whelan B, Kenny RA, Carpena-Ruiz M, Anton JM, de Antonio P, Verdejo C, Cruz-Jentoft AJ, Anton JM, Verdejo C, de Antonio P, Carpena M, Cruz-Jentoft AJ, Sanchez FJM, Alonso CF, del Castillo JG, Ferrer MF, Armengol JG, Villarroel P, Gregorio PG, Casado JMR, Leiros BG, Garcia FJG, Clemente MRP, Acha AA, Ramiez LFM, Ballesteros CM, Ibanez JMF, Andres SA, Maya RP, Soria JF, Checa M, Melich AE, Lang PO, Herrmann F, Michel JP, Cebrian A, Duiez-Domingo J, San-Martin M, Vantieghem KM, Terumalai K, Kaiser L, Trellu LT, Brandt MS, Jørgensen B, Nyhuus C, Lyager A, Hagedorn D, Holm E, Lauritsen J, Leners JC, Sibret MP, Mas MA, Renom A, Vazquez O, Miralles R, Cervera AM, Mathur A, Lord S, Mikes Z, Mikes P, Holckova J, Dukat A, Lietava J, Petrovicova J, Strelkova V, Kolesar J, Rokkedal L, Granberg P, Mortensen RS, Shipman K, Vincent B, Patel T, Yau C, Rehman R, Salam A, Ballentyne S, Aw D, Weerasuriya N, Lee S, Masud T, Barry P, O’connor M, O’sullivan F, Moriarty E, O’connor K, O’connor M, Bogen B, Bjordal JM, Kristensen MT, Moe-Nilssen R, Crome I, Lally F, Crome P, Curiale V, Custureri R, Prete C, Trasciatti S, Galliera EOO, Herrmann F, Petitpierre N, Michel JP, Kitisomprayoonkul W, Chaiwanichsiri D, Kristensen MT, Bandholm T, Bencke J, Ekdahl C, Kehlet H, Lauritsen J, Sørensen GV, Gonzalez A, Lazaro M, Gonzalez E, Ribera JM, Casado JMR, Gillett S, MacMahon M, Pedersen SJ, Borgbjerg FM, Schousboe B, Pedersen BD, Jørgensen HL, Duus BR, Lauritzen JB, Cooke J, Pillay I, Binkley N, Boonen S, Roux C, He W, Rosenberg R, Yang Z, Salonoja M, Aarnio P, Vahlberg T, Ktvelä SL, Salpakoski A, Portegijs E, Kallinen M, Sihvonen S, Kiviranta I, Alen M, Rantanen T, Sipilä S, Szczerbinska K, Sørensen GV, Lauritsen J, Vincent B, Way B, Vergis N, Battacharya B, Chatterjee A, Bryden E, Vind AB, Andersen HE, Pedersen KD, Jørgensen T, Schwarz P, Zintchouk D, Mørch M, Damsgaard EM, De Saint-Hubert M, Divoy C, Godart P, Schoevaerdts D, Swine C, Alonso CF, Sanchez FJM, del Castillo JG, Ferrer MF, Armengol JG, Villarroel P, Bravo CV, Casado JMR, Hovmand B, Larsen AE, Pedersen S, Vinkler S, Christensen K, Øresund CVU, Matera MG, Goffredo V, Franceschi M, D’onofrio G, Addante F, Gravina C, Urbano M, Seripa D, Dallapiccola B, Pilotto A, Chroinin DNI, O’brien H, Power D, Santillo E, Ventura G, Migale M, Cassano S, Cariello FP, Crane S, Takahashi P, Tung E, Chandra A, Yu-Ballard A, Hanson G, Vandewoude M, Hoeck S, Geerts J, Van Hal G, Van der Heyden J, Breda J, Weber P, Meluzínová H, Hrubanová J, Kubšová H, Polcarová V, Campbell P, Henderson E, Macmahon M, Pedersen ABL, Mørch MM, Foss CH, Franceschi M, Maggi S, Pilotto A, Noale M, Parisi G, Crepaldi G, Furusyo N, Koga T, Ohnishi H, Maeda S, Takeoka H, Toyoda K, Ogawa E, Sawayama Y, Hayashi J, Kamigaki M, Nakagawa I, Kumei Y, Hayashi N, Takasugi Y, Maggi S, Pilotto A, Noale M, Franceschi L, Parisi GC, Crepaldi G, Maggi S, Pilotto A, Franceschi M, Noale M, Parisi GC, Crepaldi G, Michael A, Bhangu A, Fisher G, Rees E, Labib M, Ogawa E, Furusyo N, Koga T, Sawayama Y, Hayashi J, Ohishi M, Takagi T, Fujisawa T, Katsuya T, Rakugi H, Pilotto A, Franceschi M, Ferrucci L, Rengo F, Bernabei R, Leandro G, Pilotto A, Franceschi M, Maggi S, Noale M, Parisi G, Crepaldi G, Cotter PE, Simon M, Quinn C, O’keeffe ST, Moy I, Crome P, Crome I, Frisher M, Daly K, Huber P, Hilleret H, Lang PO, Le Saint L, Chamot C, Giannakopoulos P, Gold G, Leckie K, Bayes H, Birschel P, Lundgren B, Eniry BM, Pillay I, Matzen LE, O’neill D, Garavan R, O’hanlon A, Mcgee H, Akdemir N, Kapucu S, Ozdemir L, Akkus Y, Balci G, Akyar I, Patacchini F, Ruggiero C, Dell’aquila G, Ferretti R, Mariani T, Gugliotta R, Cirinei E, Gasperini B, Lattanzio F, Bernabei R, Senin U, Cherubini C, Pedersen TS, Raun KN, Jespersen E, Sixt E, Takahashi P, Crane S, Tung E, Chandra A, Yu-Ballard A, Hanson G, Velghe A, Petermans J. Oral and Poster Papers Submitted for Presentation at the 5th Congress of the EUGMS “Geriatric Medicine in a Time of Generational Shift September 3–6, 2008 Copenhagen, Denmark. J Nutr Health Aging 2008. [DOI: 10.1007/bf02983206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
44
|
Gallagher D, Guerandel A, Malone K, Barry M, Barry P. Complex visual hallucinations in a psychologically normal patient. Ir Med J 2007; 100:571-572. [PMID: 17955718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
|
45
|
Gallagher P, Barry P, Liston R. Ethical challenges in contemporary medical practice--conference report. Ir Med J 2007; 100:486-7. [PMID: 17668678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
|
46
|
Abstract
BACKGROUND AND OBJECTIVE Drug therapy is necessary to treat acute illness, maintain current health and prevent further decline. However, optimizing drug therapy for older patients is challenging and sometimes, drug therapy can do more harm than good. Drug utilization review tools can highlight instances of potentially inappropriate prescribing to those involved in elderly pharmacotherapy, i.e. doctors, nurses and pharmacists. We aim to provide a review of the literature on potentially inappropriate prescribing in the elderly and also to review the explicit criteria that have been designed to detect potentially inappropriate prescribing in the elderly. METHODS We performed an electronic search of the PUBMED database for articles published between 1991 and 2006 and a manual search through major journals for articles referenced in those located through PUBMED. Search terms were elderly, inappropriate prescribing, prescriptions, prevalence, Beers criteria, health outcomes and Europe. RESULTS AND DISCUSSION Prescription of potentially inappropriate medications to older people is highly prevalent in the United States and Europe, ranging from 12% in community-dwelling elderly to 40% in nursing home residents. Inappropriate prescribing is associated with adverse drug events. Limited data exists on health outcomes from use of inappropriate medications. There are no prospective randomized controlled studies that test the tangible clinical benefit to patients of using drug utilization review tools. Existing drug utilization review tools have been designed on the basis of North American and Canadian drug formularies and may not be appropriate for use in European countries because of the differences in national drug formularies and prescribing attitudes. CONCLUSION Given the high prevalence of inappropriate prescribing despite the widespread use of drug-utilization review tools, prospective randomized controlled trials are necessary to identify useful interventions. Drug utilization review tools should be designed on the basis of a country's national drug formulary and should be evidence based.
Collapse
Affiliation(s)
- P Gallagher
- Department of Geriatric Medicine, Cork University Hospital, Wilton, Cork, Ireland
| | | | | |
Collapse
|
47
|
Barry P. Endophthalmitis prophylaxis – an ESCRS study. Klin Monbl Augenheilkd 2007. [DOI: 10.1055/s-2007-976196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
48
|
Abstract
INTRODUCTION Many surgeons will have encountered the scissors that would not cut, and the artery clip that comes off in a deep difficult location, but it would be reasonable to assume that new instruments should be of assured quality. This study reports the surprising findings of a local quality control exercise for new instruments supplied to a single trust. MATERIALS AND METHODS Between January 2004 and June 2004, all batches of new surgical instruments ordered by the Central Sterile Supplies Department of St Bartholomew's and the Royal London Hospitals were assessed by three clinical engineers, with reference to British Standards (BS) requirements. RESULTS Of 4800 instruments examined, 15% had potential problems. These included 116 with machining burrs and debris in the teeth of the tissue-holding regions, 71 defects of ratcheted instruments, 34 scissors with deficient cutting action, and 35 tissue forceps protruding guide pins. In addition, 254 instruments did not have a visible manufacturer's mark. CONCLUSIONS This study demonstrates the value of local quality control for surgical instruments. This is of importance in an increasingly hazard-conscious environment, where there are concerns over instrument sterilisation, surgical glove puncture and the potential for transmission of blood-borne and prion diseases.
Collapse
Affiliation(s)
- T Brophy
- Department of Clinical Physics, St Bartholomew's and Royal London HospitalsLondon, UK
| | - PD Srodon
- Department of Vascular Surgery, St Bartholomew's and Royal London HospitalsLondon, UK
| | - C Briggs
- Department of Clinical Physics, St Bartholomew's and Royal London HospitalsLondon, UK
| | - P Barry
- Department of Clinical Physics, St Bartholomew's and Royal London HospitalsLondon, UK
| | - J Steatham
- Department of Clinical Physics, St Bartholomew's and Royal London HospitalsLondon, UK
| | - MJ Birch
- Department of Clinical Physics, St Bartholomew's and Royal London HospitalsLondon, UK
| |
Collapse
|
49
|
Abstract
Abstract
Background
Surgery plays a dominant role in the initial and subsequent treatment of retroperitoneal liposarcoma (RPLS). This study was a review of outcomes of patients treated at the Royal Marsden Hospital.
Methods
Records of all patients who had surgery for RPLS since 1990 were reviewed, with particular attention to local recurrence and disease-specific survival. Patients with primary RPLS and those with recurrent RPLS, who had palliative surgery after a variable number of operations performed elsewhere, were considered separately.
Results
Seventy-two patients had surgery for primary RPLS, over half of whom underwent resection of a contiguous organ to achieve clearance. Follow-up of at least 12 months was available for 58 patients. Thirty-four patients had no evidence of recurrence after median follow-up of 26 (range 12–151) months. Low-grade tumour and macroscopic clearance of tumour were significantly associated with a reduced risk of local recurrence and improved survival. Forty-seven patients had palliative surgery for recurrent RPLS. Median survival from time of last operation to death was 27 (range 0–79) months. Follow-up was to a median of 68 (range 14–261) months.
Conclusion
Patients with low-grade RPLS that has been completely resected at the initial operation have the most favourable prognosis. Palliative resection is worthwhile to treat troublesome symptoms of recurrence
Collapse
Affiliation(s)
- S J Neuhaus
- Melanoma/Sarcoma Unit, The Royal Marsden Hospital NHS Trust, Fulham Road, London SW3 6JJ, UK
| | | | | | | | | | | |
Collapse
|
50
|
Fitzgerald J, Sena M, Vandewalker K, Johnson J, Barry P, Griffey S, Tarantal A, McChesney M, Ramsamooj R, Perez R. Enhanced pretransplant innate immunity predicts rejection in primate vascular allografts: An infectious etiology? J Surg Res 2004. [DOI: 10.1016/j.jss.2004.07.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|